KRAS and neoplasm: Analysis of 175 tumour tissues from The Cancer Genome Atlas (TCGA) revealed a positive correlation between mRNA levels of KRAS and NRF2. Furthermore, PDAC patients with high expression of KRAS and NRF2 had significantly poorer survival than patients with lower expression (Di Giorgio et al., 2023) (Figure 3B).